NRX Pharmaceuticals Analyst Ratings
NRX Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest NRX Pharmaceuticals (NRXP) rating was a reiterated with a price target of $0.00 to $2.00. The current price NRX Pharmaceuticals (NRXP) is trading at is $1.22, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/02/2023 | 63.93% | HC Wainwright & Co. | → $2 | Reiterates | → Buy |
| 11/09/2022 | 227.87% | Ascendiant Capital | → $4 | Initiates Coverage On | → Buy |
| 06/30/2022 | 63.93% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 02/02/2023 | 63.93% | HC 溫賴特 & 有限公司. | → 2 美元 | 重申 | → 購買 |
| 11/09/2022 | 227.87% | 上升資本 | → 4 美元 | 啟動覆蓋範圍 | → 購買 |
| 2022 年 06 月 30 日 | 63.93% | HC 溫賴特 & 有限公司. | → 2 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for NRX Pharmaceuticals (NRXP)?
NRX 製藥（NRXP）的目標價格是多少？
The latest price target for NRX Pharmaceuticals (NASDAQ: NRXP) was reported by HC Wainwright & Co. on February 2, 2023. The analyst firm set a price target for $2.00 expecting NRXP to rise to within 12 months (a possible 63.93% upside). 3 analyst firms have reported ratings in the last year.
威萊特有限公司於 2023 年 2 月 2 日報導了 NRX 製藥（納斯達克代碼：NRXP）的最新價格目標。該分析師公司設定了 2.00 美元的價格目標，預計 NRXP 將在 12 個月內上升（可能為 63.93％ 的上行情況）。3 家分析師公司在去年報告了評級。
What is the most recent analyst rating for NRX Pharmaceuticals (NRXP)?
NRX 製藥（NRXP）的最新分析師評級為何？
The latest analyst rating for NRX Pharmaceuticals (NASDAQ: NRXP) was provided by HC Wainwright & Co., and NRX Pharmaceuticals reiterated their buy rating.
NRX 製藥公司（納斯達克：NRXP）的最新分析師評級由 HC 溫賴特公司提供，NRX 製藥重申其購買評級。
When is the next analyst rating going to be posted or updated for NRX Pharmaceuticals (NRXP)?
NRX 製藥（NRXP）的下一個分析師評級何時發布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NRX Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NRX Pharmaceuticals was filed on February 2, 2023 so you should expect the next rating to be made available sometime around February 2, 2024.
分析師在進行了廣泛的研究之後抵達股票評級，其中包括通過公共財務報表，與 NRX Pharmacery 的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。NRX 製藥的最後評級於 2023 年 2 月 2 日提交，因此您應該期望下一個評級將在 2024 年 2 月 2 日左右的某個時間提供。
Is the Analyst Rating NRX Pharmaceuticals (NRXP) correct?
NRX 製藥（NRXP）的分析師評級是否正確？
While ratings are subjective and will change, the latest NRX Pharmaceuticals (NRXP) rating was a reiterated with a price target of $0.00 to $2.00. The current price NRX Pharmaceuticals (NRXP) is trading at is $1.22, which is within the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的 NRX 製藥（NRXP）評級重申，目標價格為 0.00 美元至 2.00 美元。當前價格 NRX 製藥（NRXP）的交易價格為 1.22 美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。
